Nov 16, 2022 7:00am EST Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience
Nov 9, 2022 7:00am EST Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
Nov 7, 2022 7:00am EST Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Oct 25, 2022 7:00am EDT Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
Oct 3, 2022 7:00am EDT Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
Sep 22, 2022 7:00am EDT Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain
Sep 15, 2022 7:00am EDT Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)
